title: 5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia.
abstract: Previous studies from our laboratory demonstrated that zileuton, a selective 5-lipoxygenase (5-LOX) inhibitor, attenuates ischemic brain damage in rats of focal cerebral ischemia. Enormous evidences showed that inflammatory reaction and neuronal apoptosis are the two important pathophysiological events in ischemia-induced brain damage. Our previous studies demonstrate that zileuton attenuates ischemic brain damage via inhibiting inflammatory reaction. The present study was performed to explore whether 5-LOX inhibitor zileuton attenuates neuronal apoptosis following focal cerebral ischemia and further investigate the potent mechanisms underlying its neuroprotection. Adult male Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (MCAO) for 72 h, then received intragastric gavage with zileuton or vehicle as a bolus after the onset of MCAO. Neurological deficit scores, cerebral infarct volume, and neuronal damage were measured 72 h after MCAO. TUNEL staining was performed to measure the extent of neuronal apoptosis. Reverse transcription-polymerase chain reaction was performed to determine the expression of caspase-1 mRNA. Western blot was performed to determine the expression of procaspase-3 and cleaved caspase-3 in rat brain. Neurological deficit scores, infarct volume, and neuronal damage were significantly attenuated by administration of zileuton. MCAO caused the elevation of neuronal apoptosis, which was significantly inhibited by the administration of zileuton. MCAO caused the over-expression of caspase-1 and cleaved caspase-3, both of which were significantly inhibited by the administration of zileuton. Expression of procaspase-3 was reduced after MCAO, which was significantly up-regulated by administration of zileuton. Our studies suggested that 5-LOX inhibitor zileuton reduces MCAO-induced brain damage and neuronal apoptosis, which might be associated with the inhibition of caspase-1 and the regulation of caspase-3.
authors.affiliation: Department of Neurosurgery, Fujian Medical University Union Hospital, Fujian Neurosurgical Institute, 29# Xinquan Road, Fuzhou, Fujian, 350001, China.
authors.forename: Song-sheng
authors.initials: SS
authors.lastname: Shi
authors.forename: Wei-zhong
authors.initials: WZ
authors.lastname: Yang
authors.forename: Xian-kun
authors.initials: XK
authors.lastname: Tu
authors.forename: Chun-hua
authors.initials: CH
authors.lastname: Wang
authors.forename: Chen-mei
authors.initials: CM
authors.lastname: Chen
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D001921:Brain / Q000187:drug effects; D001930:Brain Injuries / Q000188:drug therapy* / Q000378:metabolism; D020170:Caspase 1 / Q000096:biosynthesis; D053148:Caspase 3 / Q000096:biosynthesis; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D016859:Lipoxygenase Inhibitors; D018696:Neuroprotective Agents; D001094:Arachidonate 5-Lipoxygenase; D053148:Caspase 3; D020170:Caspase 1; C063449:zileuton; D006918:Hydroxyurea